Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Anshul ShahJonathan C ToshApoorva AmbavaneAndreas NikolaouCosmina HogeaYevgeniy SamyshkinBoris GorshEric M MaieseFeng WangPublished in: ClinicoEconomics and outcomes research : CEOR (2021)
BIA indicates that adoption of belamaf in this patient population would be budget neutral for a US health plan.